Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease

Chengjie Xiong, Hua Weng, David A. Bennett, Patricia A. Boyle, Raj C. Shah, Scot Fague, Charles B. Hall, Richard B. Lipton, John C. Morris

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background/Aims: Cognitive batteries routinely used by the Alzheimer's disease (AD) research community may contain items that are uninformative for tracking disease progression to power clinical trials on early stage AD. We aim to identify the subsets of the most informative items from an existing cognitive battery to better power clinical trials on early AD. Methods: Longitudinal change in item scores from the battery was associated with the onset of mild cognitive impairment (MCI) in 1,513 elderly individuals. Items whose longitudinal changes were correlated with the onset of MCI were selected as informative for tracking the early cognitive progression. Results: 226 items in the battery were annually assessed over a follow-up of up to 13 years. Changes of item scores over time from 187 items were significantly correlated with the onset of MCI. For clinical trials on preclinical AD and on MCI, informative items permit smaller or similar sample sizes as compared to the entire battery, whereas uninformative items require much larger sample sizes. Conclusions: Longitudinal changes in item scores from about 17% of items in the cognitive battery are uninformative for tracking early disease progression. Clinical trials on early AD can be better powered using informative items rather than the entire battery.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalNeuroepidemiology
Volume43
Issue number2
DOIs
StatePublished - Apr 18 2014

Keywords

  • Alzheimer's disease
  • Clinical trial design
  • Cognitive decline
  • Mild cognitive impairment
  • Power

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease'. Together they form a unique fingerprint.

Cite this